ABOUT US

Altimmune (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). Please contact us for more information

Management Team

Our management team has broad expertise across scientific and business operations, inventing compounds and advancing product candidates through clinical development.

Vipin K. Garg, Ph.D.

Vipin K. Garg, Ph.D.

President and Chief Executive Officer

Scot Roberts, Ph.D.

Scot Roberts, Ph.D.

Chief Scientific Officer

Will Brown

Will Brown

Chief Financial Officer

M. Scott Harris, M.D.

M. Scott Harris, M.D.

Chief Medical Officer

Bertrand Georges, Ph.D.

Bertrand Georges, Ph.D.

Chief Technology Officer

José Ochoa

José Ochoa

Chief Business Officer

Board of Directors

Wayne Pisano

Wayne Pisano

Director

John M. Gill

John M. Gill

Director

Vipin K. Garg, Ph.D.

Vipin K. Garg, Ph.D.

President and Chief Executive Officer

Partnerships

We believe strategic partnerships break barriers to innovation and we continuously evaluate partnership opportunities. Contact Jose Ochoa, Chief Business Officer, for partnership inquiries.

For partnership opportunities contact:

Jose Ochoa
Chief Business Officer
jochoa@altimmune.com